Literature DB >> 11353655

In vitro activities of three nonfluorinated quinolones against representative bacterial isolates.

A L Barry1, P C Fuchs, S D Brown.   

Abstract

In vitro susceptibility tests were performed to document the inhibitory activities of three nonfluorinated quinolone (NFQ) compounds (PGE 9262932, PGE 9509924, and PGE 4175997) compared to those of ciprofloxacin, levofloxacin, and trovafloxacin against 3,030 bacterial isolates. The spectra of the NFQ agents included most gram-positive species as well as quinolone-susceptible Enterobacteriaceae. Ciprofloxacin-resistant, methicillin-resistant Staphylococcus aureus strains were inhibited by the NFQ series at < or =1.0 microg/ml. The NFQ compounds were not very active against Pseudomonas aeruginosa and most other nonfermentative gram-negative bacilli. Against other species, the potency of the NFQ agents was similar to that of trovafloxacin. Continued investigation of the NFQ compounds seems to be warranted.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11353655      PMCID: PMC90575          DOI: 10.1128/AAC.45.6.1923-1927.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  2 in total

Review 1.  New uses for new and old quinolones and the challenge of resistance.

Authors:  D C Hooper
Journal:  Clin Infect Dis       Date:  2000-02       Impact factor: 9.079

Review 2.  Fluoroquinolone toxicity profiles: a review focusing on newer agents.

Authors:  B A Lipsky; C A Baker
Journal:  Clin Infect Dis       Date:  1999-02       Impact factor: 9.079

  2 in total
  6 in total

1.  In vivo efficacies and pharmacokinetics of DX-619, a novel des-fluoro(6) quinolone, against Streptococcus pneumoniae in a mouse lung infection model.

Authors:  Yuichi Fukuda; Katsunori Yanagihara; Hideaki Ohno; Yasuhito Higashiyama; Yoshitsugu Miyazaki; Kazuhiro Tsukamoto; Yoichi Hirakata; Kazunori Tomono; Yohei Mizuta; Takayoshi Tashiro; Shigeru Kohno
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

2.  In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.

Authors:  Heather J Adam; Nancy M Laing; C Richard King; Ben Lulashnyk; Daryl J Hoban; George G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2009-09-08       Impact factor: 5.191

3.  In vitro activities of novel nonfluorinated quinolones PGE 9262932 and PGE 9509924 against clinical isolates of Staphylococcus aureus and Streptococcus pneumoniae with defined mutations in DNA gyrase and topoisomerase IV.

Authors:  Mark E Jones; Ian A Critchley; James A Karlowsky; Renée S Blosser-Middleton; Franz-Josef Schmitz; Clyde Thornsberry; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

4.  Prevalence and characterization of invasive isolates of Streptococcus pyogenes with reduced susceptibility to fluoroquinolones.

Authors:  Jeff Powis; Allison McGeer; Carla Duncan; Ryan Goren; Joyce C S de Azavedo; Darrin J Bast; Sylvia Pong-Porter; Tony Mazzulli; Karen Green; Barbara Willey; Donald E Low
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

Review 5.  Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin.

Authors:  Bela Kocsis; J Domokos; D Szabo
Journal:  Ann Clin Microbiol Antimicrob       Date:  2016-05-23       Impact factor: 3.944

6.  In Vitro Resistance Development to Nemonoxacin in Streptococcus pneumoniae: A Unique Profile for a Novel Nonfluorinated Quinolone.

Authors:  Siddhartha Roychoudhury; Kelly Makin; Tracy Twinem; Robert Leunk; Ming Chu Hsu
Journal:  Microb Drug Resist       Date:  2016-06-07       Impact factor: 3.431

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.